Section Arrow
Quote
PRAX.NASDAQ
- Praxis Precision Medicines
Quotes are at least 15-min delayed:2025/11/19 11:05 EST
Regular Hours
Last
 182.9
-1.23 (-0.67%)
Day High 
191.23 
Prev. Close
184.13 
1-M High
206.71 
Volume 
101.76K 
Bid
181.49
Ask
184.7
Day Low
181.025 
Open
188.08 
1-M Low
154.45 
Market Cap 
4.60B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 178.65 
20-SMA 182.87 
50-SMA 112.99 
52-W High 206.71 
52-W Low 26.7 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-12.97/-13.20
Enterprise Value
4.60B
Balance Sheet
Book Value Per Share
13.74
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
8.55M
Operating Revenue Per Share
0.08
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NUVBNuvation Bio6.55+1.75+36.46%-- 
ASBPAspire Biopharma Holdings Inc.0.0974-0.0083-7.85%-- 
OLMAOlema Pharmaceuticals22.53+2.39+11.87%-- 
CYPHCypherpunk Technologies Inc.3.07+0.1+3.37%-- 
KZIAKazia Therapeutics Limited7.98+2.22+38.54%-- 
Quotes are at least 15-min delayed：2025/11/19 11:05 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized bya neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.